Literature DB >> 33317068

Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.

Sang Chul Shin1, Ashraf K El-Damasy2,3, Ju Hyeon Lee2, Seon Hee Seo2, Ji Hyun Kim4, Young Ho Seo4, Yuri Lee5, Ji Hoon Yu5, Eun Kyoung Bang2, Eunice EunKyeong Kim1, Gyochang Keum2,6.   

Abstract

Inhibition of the molecular chaperone heat shock protein 90 (Hsp90) represents a promising approach for cancer treatment. BIIB021 is a highly potent Hsp90 inhibitor with remarkable anticancer activity; however, its clinical application is limited by lack of potency and response. In this study, we aimed to investigate the impact of replacing the hydrophobic moiety of BIIB021, 4-methoxy-3,5-dimethylpyridine, with various five-membered ring structures on the binding to Hsp90. A focused array of N7/N9-substituted purines, featuring aromatic and non-aromatic rings, was designed, considering the size of hydrophobic pocket B in Hsp90 to obtain insights into their binding modes within the ATP binding site of Hsp90 in terms of π-π stacking interactions in pocket B as well as outer α-helix 4 configurations. The target molecules were synthesized and evaluated for their Hsp90α inhibitory activity in cell-free assays. Among the tested compounds, the isoxazole derivatives 6b and 6c, and the sole six-membered derivative 14 showed favorable Hsp90α inhibitory activity, with IC50 values of 1.76 µM, 0.203 µM, and 1.00 µM, respectively. Furthermore, compound 14 elicited promising anticancer activity against MCF-7, SK-BR-3, and HCT116 cell lines. The X-ray structures of compounds 4b, 6b, 6c, 8, and 14 bound to the N-terminal domain of Hsp90 were determined in order to understand the obtained results and to acquire additional structural insights, which might enable further optimization of BIIB021.

Entities:  

Keywords:  BIIB021 analogs; Hsp90 inhibitors; X-ray crystallography; hydrophobic binding pocket; isoxazole

Mesh:

Substances:

Year:  2020        PMID: 33317068      PMCID: PMC7763603          DOI: 10.3390/ijms21249377

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  51 in total

Review 1.  Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.

Authors:  Komal Jhaveri; Tony Taldone; Shanu Modi; Gabriela Chiosis
Journal:  Biochim Biophys Acta       Date:  2011-10-29

2.  Molecular replacement with MOLREP.

Authors:  Alexei Vagin; Alexei Teplyakov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

3.  Facile synthesis of 8-azido-6-benzylaminopurine.

Authors:  Mikhail Yu Steklov; Vitali I Tararov; Georgy A Romanov; Sergey N Mikhailov
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2011 Jul-Aug       Impact factor: 1.381

4.  Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.

Authors:  Yuval Samuni; Hisanari Ishii; Fuminori Hyodo; Uri Samuni; Murali C Krishna; Sara Goldstein; James B Mitchell
Journal:  Free Radic Biol Med       Date:  2010-03-06       Impact factor: 7.376

Review 5.  HSP90 and the chaperoning of cancer.

Authors:  Luke Whitesell; Susan L Lindquist
Journal:  Nat Rev Cancer       Date:  2005-10       Impact factor: 60.716

Review 6.  HSP90 manages the ends.

Authors:  Diane C DeZwaan; Brian C Freeman
Journal:  Trends Biochem Sci       Date:  2010-03-16       Impact factor: 13.807

7.  Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.

Authors:  Tony Taldone; Pallav D Patel; Maulik Patel; Hardik J Patel; Christopher E Evans; Anna Rodina; Stefan Ochiana; Smit K Shah; Mohammad Uddin; Daniel Gewirth; Gabriela Chiosis
Journal:  J Med Chem       Date:  2013-08-21       Impact factor: 7.446

8.  Structural-thermodynamic relationships of interactions in the N-terminal ATP-binding domain of Hsp90.

Authors:  Sanjay Nilapwar; Eleanor Williams; Christopher Fu; Christosmos Prodromou; Laurence H Pearl; Mark A Williams; John E Ladbury
Journal:  J Mol Biol       Date:  2009-07-21       Impact factor: 5.469

Review 9.  Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.

Authors:  Meining Wang; Aijun Shen; Chi Zhang; Zilan Song; Jing Ai; Hongchun Liu; Liping Sun; Jian Ding; Meiyu Geng; Ao Zhang
Journal:  J Med Chem       Date:  2016-02-16       Impact factor: 7.446

10.  Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.

Authors:  Dong-Jo Chang; Hongchan An; Kyoung-suk Kim; Hyun Ho Kim; Jinkyung Jung; Jung Min Lee; Nam-Jung Kim; Young Taek Han; Hwayoung Yun; Sujin Lee; Geumwoo Lee; Seungbeom Lee; Ju Sung Lee; Jong-Ho Cha; Ji-Hyeon Park; Ji Won Park; Su-Chan Lee; Sang Geon Kim; Jeong Hun Kim; Ho-Young Lee; Kyu-Won Kim; Young-Ger Suh
Journal:  J Med Chem       Date:  2012-12-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.